All In Biotech

Drug Trial Radar · NCT02510001

MEK and MET Inhibition in Colorectal Cancer

A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

Nov 2014

Primary completion

Dec 3, 2018

Study completion Dec 3, 2018

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Queen's University, Belfast; Oxford University Hospitals NHS Trust; Velindre NHS Trust; University Hospital, Antwerp; Hospital Vall d'Hebron; Saint Antoine University Hospital; European Georges Pompidou Hospital; Pfizer; University of Turin, Italy; Belfast Health and Social Care Trust; Beaumont Hospital; European Commission; Array BioPharma; University of Paris 5 - Rene Descartes
First posted
Jul 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer. The first part of the trial will see what doses of the two drugs can safely be given together. Once the investigators have identified a suitable dose combination they will look at how effective treatment is in bowel cancers where either the RAS gene is mutated, or MET is over-active. In the trial the investigators will look at samples of blood, skin and tumour to check the drugs are working in the way expected. The trial will take place in three sites in the UK and 5 sites in Europe. The trial is funded as part of the European commission's FP7 program.

Conditions

  • Solid Tumor
  • Colorectal Cancer

Interventions

  • PF-02341066Drug

    PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously

  • PD-0325901Drug

    PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.

  • BinimetinibDrug

    Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066Time frame: Dose Escalation Phase: treatment Cycle 1 28 days (plus 7 day run-in for PD-0325901/PF-02341066 combination)
  2. Clinical Response to Binimetinib Combined With PF-02341066Time frame: Dose Expansion phase: change from baseline and up to 12 months.
  3. Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066Time frame: Dose Escalation Phase: treatment Cycle 1 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oxford University Hospital NHS Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.